Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Kestra Medical Technologies / Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/kestra-medical-technologies-inc">Kestra Medical Technologies</a> is a rapidly growing player in the wearable cardioverter defibrillator (WCD) market, challenging the incumbent with its modern, patient-centric ASSURE® system.</li>
  <li>The company is demonstrating impressive top-line growth, with fiscal year 2026 revenue increasing by 59% year-over-year, driven by market share gains and expansion of the WCD market.</li>
  <li>Despite strong revenue growth, Kestra is not yet profitable and faces significant competition from established medical device companies, making its path to sustained profitability a key factor to monitor.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Kestra Medical Technologies is a rapidly growing player in the wearable cardioverter defibrillator (WCD) market, challenging the incumbent with its modern, patient-centric ASSURE® system.
  The company is demonstrating impressive top-line growth, with fiscal year 2026 revenue increasing by 59% year-over-year, driven by market share gains and expansion of the WCD market.
  Despite strong revenue growth, Kestra is not yet profitable and faces significant competition from established medical device companies, making its path to sustained profitability a key factor to monitor.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Kestra Medical Technologies (KMTS US) - Aug 2026

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Kestra Medical Technologies / Equity Capital Markets

<ul>
<li>Wearable defibrillator maker, Kestra Medical Technologies (KMTS US) is set to debut on Thursday (3/6) seeking a cash raise of up to $160 million and a valuation between $667m-$762.</li>
<li>The deal is considered well-oversubscribed from continued 1-on-1 conversions and high-quality engagements.</li>
<li>Given the financials and sector in which this company operates in and the strong backing (Bain Capital), we continue to believe this IPO will be well-received despite any market volatility.</li>
</ul>


Wearable defibrillator maker, Kestra Medical Technologies (KMTS US) is set to debut on Thursday (3/6) seeking a cash raise of up to $160 million and a valuation between $667m-$762.
The deal is considered well-oversubscribed from continued 1-on-1 conversions and high-quality engagements.
Given the financials and sector in which this company operates in and the strong backing (Bain Capital), we continue to believe this IPO will be well-received despite any market volatility.


Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility

<ul>
<li>Kestra was founded in 2014 by Bain Capital private equity and leaders from the external (AED) and internal (ICD) defibrillation industries. </li>
<li>The company is seeking a valuation between $667m-$762m based on the $14-$16 range.</li>
<li>Given the financials, sector in which this company operates in and the strong backing, it is our early opinion that the IPO will likely be well-received.</li>
</ul>


Kestra was founded in 2014 by Bain Capital private equity and leaders from the external (AED) and internal (ICD) defibrillation industries. 
The company is seeking a valuation between $667m-$762m based on the $14-$16 range.
Given the financials, sector in which this company operates in and the strong backing, it is our early opinion that the IPO will likely be well-received.


Kestra Medical Technologies, Ltd (KMTS): Defibrillator Maker to Break IPO Thaw

<ul>
<li>The company, which debuted in March 2025 with 11.9 million shares priced at $17.00—above its $14–$16 range—opened at $22.95 for a 35% gain.</li>
<li>Following its debut, Kestra Medical Technologies (KMTS US)  hit an early post-IPO high of $26.15 but traded as low as $13.25 in the summer.</li>
<li>The stock has jumped in the last month on the heels of strong first-quarter financial results, where the company not only beat revenue expectations but also raised full-year guidance.</li>
</ul>


The company, which debuted in March 2025 with 11.9 million shares priced at $17.00—above its $14–$16 range—opened at $22.95 for a 35% gain.
Following its debut, Kestra Medical Technologies (KMTS US)  hit an early post-IPO high of $26.15 but traded as low as $13.25 in the summer.
The stock has jumped in the last month on the heels of strong first-quarter financial results, where the company not only beat revenue expectations but also raised full-year guidance.


Kestra Medical Technologies (KMTS) Six Month Summary: Steady Rebound Amid Sector Volatility

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Artificial-Intelligence-Powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the company is seeking a market value of $430M.</li>
<li>Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is developing aprevo for cervical spine fusion surgeries, which is expected to be commercialized in 2026.</li>
<li>Carlsmed estimates there is a total addressable market of $13.4B for aprevo in the U.S. Aprevo may also benefit other musculoskeletal applications beyond the spine, unlocking greater market potential.</li>
</ul>


Artificial-Intelligence-Powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the company is seeking a market value of $430M.
Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is developing aprevo for cervical spine fusion surgeries, which is expected to be commercialized in 2026.
Carlsmed estimates there is a total addressable market of $13.4B for aprevo in the U.S. Aprevo may also benefit other musculoskeletal applications beyond the spine, unlocking greater market potential.


Carlsmed (CARL US) IPO: Will Take Time to Straighten Its Spine, Can Subscribe Just for Listing Gain

United States

Kestra Medical Technologies, Inc. operates as a wearable medical device and digital healthcare company. The Company develops cardiac recovery systems, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single unified solution. Kestra Medical Technologies serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kestra Medical Technologies (KMTS US)

Primer: Kestra Medical Technologies (KMTS US) - Aug 2026

Kestra Medical Technologies is a rapidly growing player in the wearable cardioverter defibrillator (WCD) market, challenging the incumbent with...

αSK Primers

Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility

Wearable defibrillator maker Kestra Medical Technologies set to debut with IPO seeking up to $160 million, backed by Bain Capital and expected to...

IPO Boutique

Kestra Medical Technologies, Ltd (KMTS): Defibrillator Maker to Break IPO Thaw

Kestra, founded in 2014 by Bain Capital and industry leaders, seeks a valuation of $667m-$762m in its upcoming IPO, expected to be well-received.

IPO Boutique

Kestra Medical Technologies (KMTS) Six Month Summary: Steady Rebound Amid Sector Volatility

Kestra Medical Technologies stock rebounds after strong first-quarter results. The stock has traded well in its first six months amidst a bit of...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Kestra Medical Technologies (KMTS US) - Aug 2026

Kestra Medical Technologies is a rapidly growing player in the wearable cardioverter defibrillator (WCD) market, challenging the incumbent with...

αSK Primers

Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility

​Wearable defibrillator maker Kestra Medical Technologies set to debut with IPO seeking up to $160 million, backed by Bain Capital and expected to...

IPO Boutique

Kestra Medical Technologies, Ltd (KMTS): Defibrillator Maker to Break IPO Thaw

​Kestra, founded in 2014 by Bain Capital and industry leaders, seeks a valuation of $667m-$762m in its upcoming IPO, expected to be well-received.

IPO Boutique

Kestra Medical Technologies (KMTS) Six Month Summary: Steady Rebound Amid Sector Volatility

​Kestra Medical Technologies stock rebounds after strong first-quarter results. The stock has traded well in its first six months amidst a bit of...

IPO Boutique

Carlsmed (CARL US) IPO: Will Take Time to Straighten Its Spine, Can Subscribe Just for Listing Gain

Artificial-intelligence-powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the...

Tina Banerjee

Wearable defibrillator maker Kestra Medical Technologies set to debut with IPO seeking up to $160 million, backed by Bain Capital and expected to...

Kestra, founded in 2014 by Bain Capital and industry leaders, seeks a valuation of $667m-$762m in its upcoming IPO, expected to be well-received.

Kestra Medical Technologies stock rebounds after strong first-quarter results. The stock has traded well in its first six months amidst a bit of...